Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVP-10
- Development stage
- Preclinical
- Lead developer
- Avipep
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AVP-10 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Avipep for the treatment of CD30-positive lymphomas, including Hodgkin lymphoma and anaplastic large cell lymphoma. The drug utilizes Avipep's proprietary "Avibody" technology, which employs small-format, high-affinity antibody fragments (diabodies) designed for superior tumor penetration and rapid systemic clearance compared to full-length antibodies. AVP-10 consists of a CD30-specific Avibody conjugated to the potent cytotoxic agent monomethyl auristatin F (MMAF), a tubulin inhibitor. Preclinical data, including studies in Karpas-299 xenograft models, have demonstrated significant anti-tumor activity. The program is currently in preclinical development with the goal of advancing into Phase 1 clinical trials.
- Other names
- ADC AVP10
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD30 (CD30 antigen)
Beyond the preview
Go deeper on AVP-10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVP-10.